Elanco Animal Health Incorporated (ELAN)
$
17.7
-0.26 (-1.47%)
Key metrics
Financial statements
Free cash flow per share
0.7149
Market cap
8.8 Billion
Price to sales ratio
1.9611
Debt to equity
0.6213
Current ratio
2.5963
Income quality
1.3180
Average inventory
1.6 Billion
ROE
0.0674
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Elanco Animal Health Incorporated is an established player in the animal health sector, innovating and developing a diverse array of products designed for both pets and farm animals. The company reported an income before tax of 488,000,000.00 showcasing its pre-tax profitability. The cost of revenue for the company is $2,530,000,000.00 showcasing its production and operational expenses, while the total costs and expenses for the company are $4,188,000,000.00 reflecting its overall spending. Additionally, Elanco reported selling, general, and administrative expenses of $1,314,000,000.00 indicating its operational overhead costs. The weighted average number of diluted shares outstanding is 497,300,000.00 reflecting potential dilution effects. Elanco focuses on pet health with disease prevention products such as parasiticides and vaccines protecting pets from common parasites like worms, fleas, and ticks under renowned brands including Seresto, Advantage, Advantix, and Advocate. It also offers therapeutics for various conditions in canines and felines under the Galliprant and Claro brands. Moreover, the company provides vaccines, antibiotics, and nutritional health products for poultry and aquaculture, alongside essential products for ruminant and swine production under the Rumensin and Baytril brands. Elanco serves a broad customer base, including third-party distributors, veterinarians, and farm animal producers ranging from beef and dairy farmers to those in the pork and poultry sectors. As an organization, Elanco Animal Health operates within the Healthcare sector, driving innovation and growth within the industry. It is a key player in the Drug Manufacturers - Specialty & Generic industry, contributing significantly to the overall market landscape. Investors seeking budget-friendly options may find the stock affordable at $14.89 making it suitable for those who are budget-conscious. Additionally, the stock has a high average trading volume of 5,572,558.00 indicating strong liquidity in the market. With a mid-range market capitalization of $8,793,607,800.00 the company is recognized as a steady performer, showcasing its reliability and consistent contributions to the animal health field.
Is Elanco Animal Health Incorporated (ELAN) a good investment?
Investing in Elanco Animal Health Incorporated (ELAN) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B, with a Bullish outlook. Always conduct your own research before investing.
What is Elanco Animal Health Incorporated (ELAN)'s stock forecast?
Analysts predict Elanco Animal Health Incorporated stock to fluctuate between $8.02 (low) and $18.09 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Elanco Animal Health Incorporated's market capitalization?
As of 2025-08-19, Elanco Animal Health Incorporated's market cap is $8,793,607,800, based on 496,814,000 outstanding shares.
How does Elanco Animal Health Incorporated compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Elanco Animal Health Incorporated has a Lower Market-Cap, indicating a difference in performance.
How can I buy Elanco Animal Health Incorporated (ELAN) stock?
To buy Elanco Animal Health Incorporated (ELAN) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ELAN. Place an order (Market, Limit, etc.).
What is the best time to invest in Elanco Animal Health Incorporated?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Elanco Animal Health Incorporated perform in the last earnings report?
Revenue: $4,439,000,000 | EPS: $0.68 | Growth: -127.20%.
Where can I find Elanco Animal Health Incorporated's investor relations reports?
Visit https://www.elanco.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Elanco Animal Health Incorporated?
You can explore historical data from here
What is the all-time high and low for Elanco Animal Health Incorporated stock?
All-time high: $36.50 (2021-08-05) | All-time low: $7.88 (2023-05-31).
What are the key trends affecting Elanco Animal Health Incorporated stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Elanco Animal Health Incorporated (NYSE:ELAN ) Q2 2025 Earnings Conference Call August 7, 2025 9:00 AM ET Company Participants Jeffrey N. Simmons - President, CEO & Director Robert M.
seekingalpha.com
I rate Elanco Animal Health Incorporated shares a Buy with a $20 fair value, driven by strong innovation and recent operational improvements. Elanco's focus on innovative products like Zenrelia and strategic divestitures positions it for growth in both companion and farm animal markets. Strong Q2 results, raised full-year guidance, and increased innovation revenue targets support my positive outlook for future growth.
benzinga.com
Elanco Animal Health Incorporated ELAN reported second-quarter 2025 results on Thursday, posting adjusted earnings per share of 26 cents, down 13% year over year.
zacks.com
Although the revenue and EPS for Elanco Animal Health (ELAN) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
zacks.com
Elanco Animal Health Incorporated (ELAN) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.2 per share. This compares to earnings of $0.3 per share a year ago.
zacks.com
Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Elanco Animal Health Incorporated (ELAN) and U.S. Physical Therapy (USPH). But which of these two stocks offers value investors a better bang for their buck right now?
prnewswire.com
TruCan Ultra CIV is the only ½ mL bivalent Canine Influenza Virus (CIV) vaccine offering broad protection against H3N2 and H3N8. 100% virus neutralization against 33 current field isolates.1 Unlike currently available products, only TruCan Ultra CIV demonstrates zero lung lesions in vaccinated dogs post H3N2 challenge.2,3,4 TruCan Ultra CIV completes Elanco's extensive line of Tru Portfolio vaccines.
benzinga.com
After years of struggling with market share losses and uneven execution, Elanco Animal Health Incorporated ELAN appears to be turning a corner.
prnewswire.com
GREENFIELD, Ind. , June 26, 2025 /PRNewswire/ -- Today, Elanco Animal Health Incorporated (NYSE: ELAN) announced the release of its 2024 Impact Report, showcasing its efforts to enhance animal care, not just improving the lives of animals but also the people who care for them.
prnewswire.com
Company expects approval and product supply in market before the end of third quarter GREENFIELD, Ind. , June 12, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) announced today that Zenrelia™ (ilunocitinib) has been granted a positive opinion by the European Medicines Agency's Committee for Veterinary Medicinal Products (CVMP), paving the way for the product's marketing authorization in the European Union in the next 60 days.
See all news
